Article Text

Download PDFPDF
Journal club
Alternatives to warfarin for the treatment of pulmonary emboli: the EINSTEIN-PE Study
  1. Gareth Hynes
  1. Correspondence to Gareth Hynes, CT2, Royal Devon and Exeter Hospital, Exeter EX2 5DW, UK; gareth.hynes{at}gmail.com

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

The last few years have seen new oral anticoagulant treatments emerge with a major advantage over conventional vitamin K antagonism with warfarin: they have a predictable dose response that negates the need for laboratory monitoring. Dabigatran (Pradaxa), a direct thrombin inhibitor, and rivaroxaban are two such medications licenced for the prevention of stroke in atrial fibrillation. Rivaroxaban (Xiralto) is a direct inhibitor of Factor Xa. The …

View Full Text

Footnotes

  • Competing interests None.

  • Provenance and peer review Not commissioned; internally peer reviewed.